Orgenesis granted €12.3m for GMP production ahead of clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Orgenesis granted €12.3m for GMP production ahead of clinical trials
Orgenesis’ Belgian subsidiary, Orgenesis SPRL, has received €12.3m ($12.8m) to further develop its Type 1 Diabetes program.

According to the company, the program’s objective is to further a cGMP (Current Good Manufacturing Practice) and to implement its technology – which looks to reprogram human liver cells into glucose-responsive, fully functional Insulin-Producing Cells (IPCs) – on an industrial scale.

Specifically, the grant will help support the GMP production of Autologous Insulin-Producing (AIP) cells for two clinical trials in Germany and Belgium.

Of the approved budget, €3.3m ($3.5m) is set aside for development work at the company’s wholly-owned contract manufacturer and development organization (CDMO), MaSTherCell S.A.

The grant comes from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) – a branch of the Administration of Wallonia, Belgium that develops incentives to boost regional innovation and research.

Vered Caplan, CEO of Orgenesis, commented "We are thankful for the continuing support of from the Walloon Region for our European activity. Through our collaboration with Pall Corporation and MaSTherCell ... our activity in the Walloon Region has been tremendously productive​."

(Feature image: iStock/jansucko)

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers